Staphylococcus aureus is a leading nosocomial pathogen of majorworldwide importance. Furthermore, it has been recently implicated inserious community acquired infections. This problem is further confoundedby the appearance of S. aureus strains exhibiting reduced susceptibility tovancomycin. Since emergence of methicillin-resistant S. aureus, theglycopeptide (vancomycin) has been the only effective treatment forstaphylococcal infections. However, lately S. aureus has developed resistanceto glycopeptides and this was associated clinically with treatment failure.This work aimed at studying the prevalence of reduced susceptibility ofS. aureus to glycopeptides (vancomycin). In this study, 500 S. aureus isolatedfrom different sample sources were collected over a period of 5 years fromhospitalized patients as well as outpatients and staff members. These isolateswere subjected to methods of identification and testing methods for the susceptibility to vancomycin in the form of drug agar dilution and E-test.Among the 500 S. aureus isolates, 1.6% showed S. aureus with reducedsusceptibility to vancomycin (hVISA) with MIC ≥ 2μg/ml of which themajority 87.5% were hospital acquired. Also a tendency to an increase invancomycin MICs (glycopeptide creep) had been observed over the 5 years.Strict measures of infection control should be applied and increasedawareness of the physicians about antibiotics abuse which is essential tocombat spread of S. aureus with reduced susceptibility to vancomycin.